Emergence of Integrase Resistance Mutations during Initial Therapy Containing Dolutegravir

Abstract

Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive manwho initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.